A carregar...
Response of Estrogen-Receptor-Positive Metastatic Breast Cancer to Olaparib in Late-Line Therapy
Monotherapy with olaparib provides significant benefits over standard therapy in patients with a germline BRCA mutation and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer, who had two or fewer previous chemotherapeutic regimens for metastatic disease. Olaparib was...
Na minha lista:
| Publicado no: | Case Rep Oncol |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6873165/ https://ncbi.nlm.nih.gov/pubmed/31762754 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503858 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|